Dementia-associated changes of immune cell composition within the cerebrospinal fluid

Stefan Busse a, Jessica Hoffmann a, Enrico Michler a, Roland Hartig b, Thomas Frodl a, Mandy Busse a,c,*

a Department of Psychiatry, University of Magdeburg, Magdeburg, Germany
b Institute of Immunology, University of Magdeburg, Magdeburg, Germany
c Experimental Obstetrics and Gynecology, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany

ARTICLE INFO

Keywords:
Alzheimer’s disease
Vascular dementia
Frontotemporal dementia
Monocytes
T cells

ABSTRACT

Inflammation and alterations in essential protein structures in the brain might also change the cellular distribution in the cerebrospinal fluid (CSF).

Using flow cytometry, we analyzed cell populations of the innate and adaptive immune system associated with the most frequent forms of dementias. We included patients with mild cognitive impairment (MCI; N = 33), Alzheimer’s disease (AD; N = 90), vascular dementia (VD; N = 35) and frontotemporal dementia (FTD; N = 17) at the time of diagnosis, before onset of treatment and 11 elderly non-demented individuals. Dependent on the form of dementia, an increased frequency of CD14⁺ monocytes, NK cells and NKT cells was measured. Within the T cell population, a dementia-associated shift from central memory towards (late-stage) effector cells was detected. T cells and NKT cells were correlated with MMSE, NK and NKT cells were correlated with ptau, CD14⁺ monocytes and NK cells were correlated with Amyloid-β₁–₄₀.

Our data suggest that each investigated immune cell type is involved in dementia-associated alterations within the CSF, possibly having distinct functions in their pathogenesis.

1. Introduction

Demographic changes due to an ongoing aging population take place throughout the world. Europeans especially from Italy and Germany belong to the oldest populations in the world (Ferrucci et al., 2008). Aging has a profound impact on the immune system, affecting both the innate and the adaptive part and seems to contribute to a chronic low-grade inflammatory state. Consequently, the frequency of age-related disorders such as atherosclerosis, type II diabetes and Alzheimer’s disease (AD) increases with age (Castelo-Branco and Soveral, 2014). AD was only recently added to the list of the leading causes of death and the proportion of people dying of it will probably grow substantially in the future (Ferrucci et al., 2008). Therefore, AD and dementia in general will be a major.

1.1. Health and socio-economic problem

Dementias are neurocognitive disorders caused by neurodegeneration and characterized by multiple cognitive impairments that result in the decline from previous function (LoGiudice and Watson, 2014). The main underlying causes of dementia are AD, Lewy Body dementia, frontotemporal dementia (FTD) and vascular dementia (VD) (Rizzi et al., 2014; Onyike and Diehl-Schmid, 2013; Sanford, 2018).

AD is the most common cause of dementia. This neurodegenerative disorder is indicated by senile plaques, neurofibrillary tangles or neuronal and synaptic loss. VD is caused e.g. by post-stroke, subcortical or multi-infarct dementia, diffuse white matter or strategic infarcts (Werring et al., 2010; Farooq and Gorelick, 2013). VD exhibits a comparatively abrupt onset and stepwise decline. AD and VD share several risk factors including age, major vascular risk factors (hypertension, smoking, diabetes, hypercholesterolemia, obesity), genetic variants, possibly also depression (Wuet al, 2016; Qiu et al., 2009) and inflammation. FTD is a heterogeneous group of hereditary and sporadic neurodegenerative disorders characterized by progressive deterioration of social and personal behaviour, executive functions and language, accompanied by impaired cognition (Bang et al., 2015). FTD substantially overlaps the symptoms of AD. Therefore, additionally to neurocognitive testing, such as the Mini-Mental State Examination (MMSE),
brain imaging and analysis of the cerebrospinal fluid (CSF) are important tools for the diagnosis of dementia forms.

FTD predominantly develops frontal or temporal atrophy, whereas in AD, there could be detected a more generalized brain atrophy with the focus on the medial temporal lobe structures.

Mild cognitive impairment (MCI) represents a transitional stage between normal cognition in the process of healthy aging and dementia. MCI patients show a high rate of progression to dementia over a relatively short time (Roberts and Knoopman, 2013).

In CSF it was shown that low Amyloid-β1-42 concentrations are a good biomarker for the presence of Amyloid deposition (Holtzman, 2011) and that total and phosphorylated tau indicate neurodegeneration (Goedert et al., 2017). In MCI, low Amyloid-β1-42 were determined in patients with a more advanced disease (Kennedy et al., 2012).

Due to epidemiologic, genetic and experimental evidence, immune mechanisms have come into focus recently and are now believed to contribute substantially to the risk, onset, and progression of dementia (Venegas and Heneka, 2019).

Monocytes, microglia, NK cells and NKT cells are part of the innate immune cells, B and T lymphocytes represent the adaptive immune system. It was shown that in aged persons, there is a shift of the immune system from immunoregulation towards inflammation. This chronic inflammation in the periphery, but also in the brain, might be important for the pathology of dementias (Franceschi et al., 2018; Mincuolo et al., 2016). We have recently shown alterations in the frequency of monocytes, NK cells, B cells and naïve/memory T cells in peripheral blood obtained from AD, FTD and PD patients (Busse et al., 2017). Due to a cross talk between peripheral and central immunity, which might be mediated e.g. by the release of cytokines and chemokines, these cell populations might also play an important role in dementias.

Memory T cells might exhibit several roles in the brain, protective but also detrimental ones. They might protect against infections with neurotropic pathogens, but might also be involved in autoimmunity and other inflammatory disorders (Wuet et al., 2018; Smolders et al., 2018). Microglia have an important function in the maintenance of brain homeostasis, which is lost in neurodegenerative disorders. Microglia, but also peripheral monocytes, contribute to the clearance cerebral Amyloid-β protein, a function that is deficient in dementias (Zuroff et al., 2017). The accumulation of Amyloid-β triggers neuroinflammation, leads to progressive synaptic loss, and finally results in cognitive decline.

NK(T) cells are important for host defense since they kill infected cells and secrete a broad range of cytokines and chemokines. Their role in neurodegenerative disorders remains to be clarified.

Standard CSF laboratory examinations included the number of monocytes, lymphocytes and granulocytes to exclude a bacterial or viral infection rather than having real input for pathology of dementia. Therefore, the aim of our study was to investigate the frequency of innate and adaptive immune cell populations, including monocytes, NK cells, NKT cells, B lymphocytes, T lymphocyte subpopulations in CSF from patients suffering from AD, FTD, PD and MCI. Besides, their activation state was determined. A group of non-demented, elderly persons served as control group (11 patients; 7 female, 4 male; mean age 71.18 years). These patients mainly suffered from depression and were admitted to our university hospital for a detailed diagnosis, but neither MMSE nor CSF values nor magnetic resonance imaging (MRI) measurements support a dementia diagnosis. The demographic data of the study cohort, including MMSE values, standard laboratory parameters obtained from CSF (ptau, htau, Amyloid-β1-40, Amyloid-β1-42, Amyloid-β ratio) and Q Albumin values, are shown in Table 1. Besides, routine blood analyses (including differential blood cell count, CRP level, glucose, lipids, liver enzymes, and thyroid hormones) were obtained in parallel. None of the study participants had to be excluded due to abnormal routine blood values or due to a history of immune diseases, immunomodulating treatment, cancer, chronic terminal disease, severe cardiovascular disorder, substance abuse, or severe trauma.

2.2. Flow cytometry analysis

3 ml CSF per panel were centrifuged, incubated with the primary antibodies (Abs) at 4 °C for 20 min. in the dark: FITC anti-human HLA-DR (G46-6) and PE anti-human CD3 (UCHT1) from BD Pharmingen (BD Biosciences; San Jose, CA, USA) and APC-eFluor 780 anti-human CD14 (61D3), APC-eFluor 450 anti-human CD19 (SJ25C1), APC anti-human CD56 (CMSSB), PE-Cy7 anti-human CD69 (FN5O); PE anti-human CD3 (UCHT1) from BD Pharmingen (BD Biosciences, Mountain View, CA, USA) and analyzed using FACS DIVA software 6.1.3 (BD Biosciences, Mountain View, CA, USA) and FlowJo software (Treestar Inc., Ashland, OR, USA). The data were analyzed using biexponential transformation function for complete data visualization and the frequency of cells was shown.

2.3. Statistical analysis

Statistical analysis was performed using GraphPad Prism 8.0 software. Normality of distribution was determined by Shapiro-Wilk test. Differences between groups were analyzed by Kruskal-Wallis test, followed by Dunn’s multiple comparisons test, thereby the mean rank of each group was compared with the mean rank of every other group. Differences in gender were analyzed by chi-square test. Correlation was analyzed using Spearman’s correlation. Significance was defined as follows: *p < 0.05, **p < 0.01, ***p < 0.001; ****p < 0.0001.

3. Results

Alterations in CSF innate immune cells in AD, FTD and PD compared to controls.

We have recently shown that dementia is associated with changes in the leukocyte populations in peripheral blood (Busse et al., 2017). The aim of the present study was to rule out whether an alteration in leukocyte composition is also detectable within the CSF. We used a flow cytometry approach to measure the leukocytes within the CSF; the gating strategy employed to identify the cell populations is shown in Suppl. Figure 1. CD14+ monocytes/macrophages were increased in AD compared to the level obtained in elderly non-demented controls (p = 0.0035; Fig. 1a). The activation state of CD14+ cells, measured by the expression level of HLA-DR, was unchanged (Table 2a). According to the presence or absence of CD3 expression, CD56+ cells can be divided into CD56 + CD3− NK cells and CD56 + CD3− NKT cells. Both cell types were raised in
Dementia, NK cells were enhanced in CSF of AD (p = 0.0005), FTD (p = 0.0195) and VD patients (p = 0.0088; Fig. 1b) while NKT cell levels were increased in AD (p = 0.0016) and VD patients (p = 0.0289; Fig. 1c). Furthermore, we detected a fraction of cells in CSF co-expressing CD3 and CD14, which were found in the controls as well as in demented patients (Table 2a). No differences were detected between the several

Table 1
Demographic data of the study cohort. Shown are demographic data of the included patients, total number of individuals, age, gender and MMSE. In addition, the most important CSF parameters are presented, including ptau, htau, Amyloid-β1-40, Amyloid-β1-42, Amyloid-β ratio and Q Albumin as marker for the blood-brain-barrier integrity. Shown are the p values obtained from Kruskal-Wallis analysis or chi-square test (for gender analysis).

| Characteristics | p          | controls | MCI | AD | FTD | VD |
|-----------------|------------|----------|-----|----|-----|----|
| total (n)       |            |          |     |    |     |    |
| age (years; mean) | 0.0085    | 71.18    | 77.18 | 80.01 | 79.80 | 80.24 | 79.83 | 74.94 | 78.75 |
| gender (female/male) | 0.6218  | 7/4      | 22/11 | 54/36 | 25/13 | 21/20 | 8/3  | 10/7  | 25/10 |
| MMSE (mean)     | <0.0001   | 28.09    | 26.85 | 20.75 | 23.11 | 14.71 | 5.727 | 19.24 | 18.21 |
| ptau            | <0.0001   | 47.50    | 49.16 | 84.52 | 90.28 | 83.39 | 65.36 | 46.94 | 42.66 |
| htau            | <0.0001   | 260.2    | 281.7 | 564.6 | 555.2 | 560.2 | 457.2 | 286.1 | 318.8 |
| Amyloid-β1-40   | 0.0423    | 10851    | 12231 | 12496 | 14303 | 11789 | 9612  | 11856 | 9899  |
| Amyloid-β1-42   | <0.0001   | 1076     | 755.4 | 502.6 | 551.7 | 479.7 | 445.1 | 794.7 | 663.6 |
| Amyloid-β ratio | <0.0001   | 1.080    | 0.838 | 0.459 | 0.450 | 0.466 | 0.458 | 0.788 | 0.806 |
| Q Albumin       | 0.7001    | 6.890    | 8.683 | 9.505 | 8.480 | 10.20 | 10.60 | 8.244 | 9.472 |

Fig. 1. Major changes in leukocyte frequencies in CSF from AD, FTD and VD patients. Shown are the main alterations in CSF leukocytes in patients with AD, FTD and VD compared to non-demented control individuals which include the percentages of CD14+CD3− monocytes (a), CD56−CD3−NK cells (b), CD56+CD3−NKT cells (c), CD3+CD14−T cells (d), CD4+T cells (e) and CD19+ B cells (f). Data were analyzed using Kruskal-Wallis test with Dunn’s multiple comparisons test. Shown are the mean values with SD; *p < 0.05, **p < 0.01 and ***p < 0.001 compared to non-demented controls. No significant differences were obtained between AD, FTD and VD.
Table 2: Overview about major changes in innate and adaptive immune cell populations in dementia. Shown are the mean percentages (mean (%)) and the corresponding standard deviation (SD) values from the investigated innate and adaptive immune cell populations in AD, FTD and VD compared to non-demented controls (a) or in MCI, mild, moderate and severe AD compared to non-demented individuals (b). Data were analyzed using Kruskal-Wallis test with Dunn’s multiple comparisons test. Since no significant differences were detected among the forms of dementia/MCI, the shown p values represent the difference between the form of dementia/MCI and the controls.

### Innate IS

|          | controls | AD | FTD | VD |
|----------|----------|----|-----|----|
| CD14 + CD3 | 0.056 | 0.104 | 4.146 | 6.341 | 0.0035 |
| CD14 + CD3 | 15.30 | 10.11 | 13.46 | 10.58 | ns |
| CD56 + CD3 | 1.209 | 0.962 | 5.557 | 4.462 | 0.0005 |
| CD56 + CD3 | 0.846 | 0.834 | 3.739 | 3.440 | 0.0016 |
| HLA-DR + CD14 | 14.80 | 10.10 | 16.30 | 10.70 | ns |

### Adaptive IS

|          | controls | AD | FTD | VD |
|----------|----------|----|-----|----|
| CD27 + CD4 | 80.48 | 9.963 | 72.76 | 14.68 | ns |
| CD27 + CD4 | 58.75 | 12.59 | 50.98 | 12.03 | ns |
| CD8 | 20.95 | 7.014 | 25.36 | 7.659 | ns |
| CD19 | 0.573 | 0.526 | 1.310 | 2.031 | ns |
| HLA-DR + CD3 | 3.480 | 2.488 | 5.606 | 5.920 | ns |
| CD69 + CD3 | 22.53 | 14.92 | 27.22 | 13.12 | ns |

### Alterations in CSF lymphocytes in AD, FTD and VD

The major cell population present in CSF is CD3+ T cells, and despite a trend to be decreased in all forms of dementia, significance was only obtained in VD (p = 0.0043; Fig. 1d). We measured two T cell activation markers, CD69 and HLA-DR, none showed differences between the groups (Table 2a).

T lymphocytes can be further subdivided into CD4+ and CD8+ T cells. While the frequency of CD8+ T cells was unchanged between the groups (Table 2a), the frequency of CD4+ T cells were diminished in VD (p = 0.0201; Fig. 1e). The number of B lymphocytes was very low and unchanged between the patients’ groups and controls (Fig. 1f). No differences were detected between the several forms of dementia.

### Alterations in CSF leukocytes in AD stages

According to the degree of cognitive decline, AD can be divided into a mild, moderate and severe form. Although MCI patients have only mild cognitive deficits, many of them develop dementia within the following years and therefore MCI might be seen as pre-stage dementia. Comparing the different stages of AD might give an impression of how the immune system reacts towards the disorder-specific alterations in the brain during the progression of AD. Compared to non-demented controls, the frequency of CD14+ monocytes was increased in mild (p = 0.0065) and moderate AD (p = 0.0037; Fig. 2a) with a sharp decline in severe AD. Altered numbers of NK cells and NKT cells were detected in MCI and all AD stages. An enhanced frequency of NK cells was present in MCI (p = 0.0166), mild (p = 0.0005), moderate (p = 0.0034) and severe AD (p = 0.0307; Fig. 2b), a higher frequency of NKT cells as compared to non-demented controls were found in MCI (p = 0.0403), mild (p = 0.0055), moderate (p = 0.0078) and severe AD (p = 0.0205; Fig. 2c).

The frequency of CD3+ T cells was not changed in MCI or AD stages compared to non-demented controls (Fig. 2d). The number of CD4+ T cells constantly declined with disease progression and reached significance in severe AD (p = 0.0492; Fig. 2e). MCI or AD stages did not lead to changes in the frequency of CD8+ T cells (Table 2b) or CD19+ B lymphocytes (Fig. 2f) compared to the control group.

### Dementia-associated changes in naive and memory T cells

CD45 can be expressed in several isoforms, allowing the discrimination between naive and memory cells: CD45RA is expressed on naive T cells and CD45RO on memory T cells. The chemokine receptor CCR7 is found on naive and central memory cells and absent on effector memory and effector cells.

In non-demented controls, only few T cells were naïve (CD45RA+CD45RO-) as well as CD4+ T cells (mean 83.35). In contrast to that, these memory T cells were diminished in MCI and all AD stages (p = 0.0021; Fig. 1e). The frequency of CD4+ T cells (Table 2b) or CD19+ B lymphocytes (Fig. 2f) were not changed in MCI or AD stages compared to non-demented controls (Fig. 2d).

The frequency of CD3+CD8+ T cells in AD (p = 0.0036) and VD (p = 0.0055) as well as central memory CD4+ T cells declined in AD (p = 0.0003) and VD (p = 0.0036) and (p = 0.0323; Fig. 3a). That was accompanied by the enhanced frequency of late-stage effector cells (CCR7+CD45RA+CD4+) in AD (p = 0.0026; Fig. 3d) and effector memory CD4+ T cells in AD (p = 0.0061) and FTD (p = 0.0008; Table 3a).

An enhanced frequency of CD45RA + CD45RO-CD8+ naive T cells...
was found in CSF in AD ($p = 0.0047$) and VD patients ($p = 0.0382$; Fig. 3e and Table 3a). CD45RA-CD45RO + memory CD8+ T cells were diminished in AD ($p = 0.0003$) and VD ($p = 0.0017$; Fig. 3f). The CCR7+CD45RO + CD8+ central memory CD8+ T cells were reduced in AD ($p = 0.0001$), FTD ($p = 0.0008$) and VD ($p = 0.0009$; Fig. 3g). Within the CD8+ T lymphocytes, the central memory cells population shifted towards late-stage effector (CCR7-CD45RA + CD8+) in AD ($p = 0.0008$), FTD ($p = 0.0507$) and VD ($p = 0.0151$; Fig. 3h), and effector memory cells in AD ($p = 0.0059$), FTD ($p = 0.0011$) and VD ($p = 0.0323$; Table 3a).

3.4. Dementia-associated changes in naive and memory T cells in stages of AD

Due to the alterations in CSF cell distribution in AD, we addressed the question whether these changes also exist in MCI and how the leukocyte frequency changes during the progression of AD.

While the population of naïve CD45RA + CD45RO- CD4+ T cells was not significantly altered in MCI or the different stages of AD (Fig. 4a), the reduction in CD45RA-CD45RO + central memory CD4+ T cells was detected in MCI ($p = 0.0016$), mild ($p = 0.0003$), moderate ($p = 0.0012$)
and severe AD (p = 0.0114; Fig. 4b and Table 4a). The population of CCR7+CD45RO+ central memory CD4+ T cells decreased in MCI (p = 0.0058), mild (p < 0.0001), moderate (p = 0.0004) and severe AD (p = 0.0255; Fig. 4c and Table 4b) compared to the control group. However, in frequency of CCR7-CD45RA+ stage effector cells CD4+ T cells was higher MCI (p = 0.0122), mild (p = 0.0011) and moderate AD (p = 0.0127; Fig. 4d and Table 4b).

Compared to non-demented control persons, the population of naïve CD45RA+CD45RO+CD8+ T cells was enhanced in MCI (p = 0.0040), mild (p = 0.0005) and moderate AD (p = 0.0037; Fig. 4e), while the CD8+ memory cells (CD45RA-CD45RO-) declined in MCI (p = 0.0012), mild (p < 0.0001), moderate (p = 0.0005) and severe AD (p = 0.0031; Fig. 4f and Table 4a). Within the CD8+ memory cells in CSF, we detected a decrease in central memory cells in MCI (p = 0.0078), mild (p < 0.0001), moderate (p < 0.0001) and severe AD (p = 0.0039; Fig. 4g and Table 4b), combined with enhanced CCR7-CD45RA+CD8+ late-stage effector cells (CD45RA-CD45RO-CD8+T cells) compared to non-demented controls. No significant differences were obtained between AD, FTD and VD.

Table 3
Overview about alterations in CD4 and CD8 T cell populations in dementia. Shown are the mean percentages (mean (%)) and the corresponding standard deviation (SD) values from the analyzed CD4 and CD8 T cell populations according to their expression of CD45RA and CD45RO (a) or based on CD45RA, CD45RO and CCR7 expression (b). The presented data were analyzed using Kruskal-Wallis test with Dunn’s multiple comparisons test. Since not significant differences were detected between the forms of dementia, the shown p values represent the difference between the form of dementia and the controls.

Table 3
| Marker | controls | AD | FVD | VD |
|--------|----------|----|-----|----|
| T cell subpopulation | mean (%) | SD | mean (%) | SD | p |
| CD45RA-CD45RO-CD8+ cells | double negative CD4+ T cells | 4.136 | 2.993 | 18.91 | 20.18 | 0.0151 | 12.25 | 12.88 | 0.05 |
| CD45RA-CD45RO-CD8+ cells | naive CD4+ T cells | 0.736 | 0.737 | 3.268 | 4.363 | ns | 2.476 | 2.511 | ns | 3.451 | 4.283 | ns |
| CD45RA-CD45RO-CD8+ cells | memory CD4+ T cells | 94.58 | 3.490 | 75.91 | 22.83 | 0.0016 | 81.88 | 13.47 | 0.0508 | 74.88 | 25.39 | 0.0068 |
| CD45RA-CD45RO-CD8+ cells | early activated CD4+ T cells | 0.563 | 0.762 | 1.918 | 2.046 | ns | 2.218 | 2.189 | ns | 4.223 | 9.777 | ns |
| CD45RA-CD45RO-CD8+ cells | double negative CD8+ T cells | 11.61 | 4.548 | 20.89 | 15.51 | 0.0047 | 16.74 | 9.150 | 0.0036 | 21.87 | 17.78 | ns |
| CD45RA-CD45RO-CD8+ cells | naive CD8+ T cells | 3.145 | 3.972 | 15.62 | 15.13 | 0.0047 | 11.22 | 10.90 | ns | 12.87 | 11.91 | 0.0382 |
| CD45RA-CD45RO-CD8+ cells | memory CD8+ T cells | 83.35 | 6.892 | 58.04 | 22.20 | 0.0003 | 66.76 | 16.52 | ns | 58.06 | 23.38 | 0.0017 |
| CD45RA-CD45RO-CD8+ cells | early activated CD8+ T cells | 1.909 | 1.872 | 5.446 | 5.200 | ns | 5.276 | 4.638 | ns | 7.194 | 10.67 | ns |
| CCR7-CD45RA+CD4+ cells | naïve CD4+ T cells | 0.855 | 0.844 | 1.803 | 1.782 | 0.0016 | 2.382 | 2.021 | ns | 5.077 | 10.47 | 0.0688 |
| CCR7-CD45RA+CD4+ cells | central memory CD4+ T cells | 78.27 | 15.01 | 37.29 | 29.92 | 0.0003 | 35.05 | 27.87 | 0.0036 | 46.70 | 31.50 | 0.0323 |
| CCR7-CD45RA+CD4+ cells | late-stage effector CD4+ T cells | 0.327 | 0.478 | 3.003 | 4.122 | 0.0268 | 2.341 | 2.454 | ns | 4.997 | 15.71 | ns |
| CCR7-CD45RA+CD4+ cells | effector memory CD4+ T cells | 16.94 | 13.88 | 41.23 | 24.34 | 0.0061 | 51.36 | 23.66 | 0.0008 | 32.64 | 22.00 | ns |
| CCR7-CD45RA+CD4+ cells | naïve CD8+ T cells | 4782 | 5.144 | 11.73 | 9.820 | ns | 10.87 | 11.41 | ns | 12.40 | 14.65 | ns |
| CCR7-CD45RA+CD4+ cells | central memory CD8+ T cells | 82.43 | 8.399 | 44.78 | 26.70 | <0.0001 | 43.01 | 25.61 | 0.0008 | 47.06 | 27.07 | 0.0009 |
| CCR7-CD45RA+CD4+ cells | late-stage effector CD8+ T cells | 0.246 | 0.568 | 8.903 | 11.19 | 0.0008 | 5.159 | 5.953 | 0.0507 | 7.577 | 10.23 | 0.0151 |
| CCR7-CD45RA+CD4+ cells | effector memory CD8+ T cells | 2736 | 3220 | 18.57 | 16.04 | 0.0059 | 29.93 | 25.22 | 0.0011 | 18.19 | 18.15 | 0.0323 |
The inactivation of naïve T cells may be important for VD. However, since their frequency in CSF was low and their occurrence was negatively correlated with MMSE (p < 0.0326; Fig. 4h) as well as effector memory CD8\(^+\) T cells (Table 4b).

### 3.5. Correlation analyses

CSF markers obtained by standard laboratory analysis (ptau, Amyloid-β ratio and Q Albumin) and the cognitive state of the patient, obtained by MMSE, were correlated with the CSF cell populations. CD56\(^+\)CD3\(^-\) NKT cells (p = 0.0217) were negatively correlated with the MMSE, indicating an enhanced frequency of these cells with decreasing MMSE values (Table 5), while CD3\(^+\) T cells were positively correlated with MMSE (p = 0.0322). CD56\(^-\) NK cells and NKT cells were positively associated with ptau (NK cells: p = 0.0058; NKT cells: p = 0.0300), a marker increased in AD at all stages with the highest concentration at mild AD (Table 1) (see Table 6).

CD14\(^+\) monocytes (p < 0.0001) and CD56\(^-\) NK cells (p = 0.0128) were positively correlated with Amyloid-β 1-40. Moreover, CD14\(^+\) monocytes (p < 0.0001), CD56\(^-\) NK cells (p = 0.0004) and CD56 + CD3\(^-\) NKT cells (p = 0.0074) were negatively correlated with the Amyloid-β ratio (p < 0.0001). No cell population was correlated with Q Albumin.

### 4. Discussion

In our recent study, we have shown that neurodegenerative disorders are associated with alterations in the cellular contribution of immune cells within the CSF.

In the cohort of elderly patients without neurodegenerative disease we found a CSF cell composition that was described by others in younger volunteers: While the frequency of B lymphocytes, NK cells and NKT cells was rather low, CD3\(^+\) T lymphocytes were the vast majority of CSF lymphocytes and most of them CD4\(^+\) T cells (Kivisakk et al., 2003). Most T cells exhibited a central memory cell phenotype, both within the CD4\(^+\) and CD8\(^+\) subpopulations. It was proposed that these CD45RO\(^+\) T cells patrol the brain boundaries for pathogens (Engelhardt and Ransohoff, 2005) while retaining their ability to return to the lymph nodes, as suggested by the expression of CCR7 (Kivisakk et al., 2004). Others found that HLA-DR was not upregulated on CSF T cells (Svenningsson et al., 1993; Svenningsson et al., 1995). It is hypothesized that activated memory T cells enter CSF directly from the systemic circulation and monitor the subarachnoid space. They retain the capacity to either initiate local immune reactions or return to secondary lymphoid organs.

It was shown that T cells circulate through the CSF for about 6 h before returning to the circulation (Engelhardt and Ransohoff, 2005), which is compared to peripheral lymphocyte recirculation a low trafficking rate (Young, 1999). T cells have been proposed to exhibit a neuroprotective effect, by the production of neurotrophins (Moalem et al., 1999; Kerstensteiner et al., 1999), the modulation of glutamate release by astrocytes and microglia (Garg et al., 2008) and by regulating innate immunity at the site of injury (Shechter et al., 2009).

In AD, FTD and VD the frequency of CD4\(^+\) and CD8\(^+\) central memory cells was severely reduced, instead an increase of CCR7-negative (late-stage) effector T cells was detected. These cells lost their lymph node homing capacity and could therefore not communicate efficiently in the periphery. On the other hand, the otherwise small fraction of naïve CD4\(^+\) T cells increased in FTD and VD, and naïve CD8\(^+\) T cells in AD and VD. The infiltration of naïve T cells into the brain might be caused by neuroinflammation (Henek et al., 2015) and/or a decreased function of the blood–CSF–barrier (Marques et al., 2013). Both indicators are discussed to have an important role in AD pathology (Henek et al., 2015). Interestingly, these changes in cell populations in CSF were already detected in MCI patients. This might be associated with the observation that MCI could be seen as the preclinical stage of AD and elevated CNS inflammation. Besides, lower Amyloid-β was detected in MCI patients (Melahet et al., 2016; Monsonet et al., 2014).

No correlation was obtained between Q Albumin and any CSF cell population. This might be explainable with the fact that we detected also no significance in Q Albumin values between non-demented controls and demented patients. However, AD patients (except mild AD) and VD patients had an increased Q Albumin value of 9.1, which indicated a disturbed blood–CSF–barrier function (Marques et al., 2013; Busse et al., 2018).

The frequency of B lymphocytes in CSF was not altered in demented patients in our study. In peripheral blood, it was detected that their frequency and their capacity to produce antibodies declines with age (Frasca and Blomberg, 2009). In plasma of AD patients, anti-Aβ antibodies were detected as well as an enhanced number of plasma cells producing antibodies toward Aβ42 prototibrils (Sollvander et al., 2015; Agrawal et al., 2018). Moreover, B cells might contribute to cognitive impairment following stroke (Doyle et al., 2015) and could be therefore important for VD. However, since their frequency in CSF was low and...
Table 4
Overview about alterations in CD4 and CD8 T cell populations in MCI and AD stages. The CD4 and CD8 T cell populations were analyzed based on their expression of CD45RA and CD45RO (a) or based on their CD45RA, CD45RO and CCR7 expression (b) in CSF obtained from patients with MCI, mild, moderate and severe AD, compared to non-demented controls. Shown are the mean percentages (mean (%)) and the corresponding standard deviation (SD) values. The data were analyzed using Kruskal-Wallis test with Dunn’s multiple comparisons test. No significant differences were detected between MCI and the separated stages of AD. Thereby, the shown p values represent the difference MCI/the stage of AD and the control group.

| marker | T cell subpopulation controls | MCI | mild AD | moderate AD | severe AD |
|--------|-------------------------------|-----|---------|-------------|-----------|
|        | mean (%) SD                   | mean (%) SD | p      | mean (%) SD | p      | mean (%) SD | p      | mean (%) SD | p     |
| CD45RA-CD45RO-CD4+ | double negative CD4+ T cells | 4.136 2.993 | 21.15 5.218 | 0.0109 0.0032 | 16.22 17.69 | 0.0059 | 16.37 21.62 | 0.0385 |
| CD45RA + CD45RO-CD4+ | naive CD4+ T cells | 0.736 0.737 | 3.335 5.218 | ns | 4.024 5.112 | ns | 3.007 3.996 | ns | 1.627 1.862 | ns |
| CD45RA-CD45RO + CD4+ | memory CD4+ T cells | 94.58 3.490 | 74.03 27.47 | 0.0016 0.0003 | 71.55 25.20 | 0.0003 | 78.86 20.33 | 0.0012 | 79.97 22.63 | 0.0114 |
| CD45RA + CD45RO + CD4+ | early activated CD4+ T cells | 0.536 0.762 | 1.481 1.785 | ns | 1.863 1.895 | ns | 1.944 2.291 | ns | 2.009 1.724 | ns |
| CD45RA-CD45RO-CD8+ | double negative CD8+ T cells | 11.61 4.548 | 20.56 20.64 | ns | 22.53 16.02 | ns | 19.05 14.51 | ns | 22.12 17.95 | ns |
| CD45RA + CD45RO-CD8+ | naive CD8+ T cells | 3.145 3.972 | 16.81 15.42 | 0.0040 0.0005 | 16.91 15.01 | 0.0005 | 16.14 16.20 | 0.0037 | 9.264 9.696 | ns |
| CD45RA-CD45RO + CD8+ | memory CD8+ T cells | 83.35 6.929 | 56.85 25.16 | 0.0012 | 54.84 23.31 | <0.0001 | 59.63 21.69 | 0.0005 | 63.15 20.34 | 0.0031 |
| CD45RA + CD45RO + CD8+ | early activated CD8+ T cells | 1.909 1.872 | 6.065 6.988 | ns | 5.734 5.086 | ns | 5.173 5.305 | ns | 5.464 5.631 | ns |
| CCR7 + CD45RA + CD4+ | naive CD4+ T cells | 0.855 0.844 | 15.72 17.68 | ns | 12.01 9.707 | ns | 12.04 10.10 | ns | 9.618 9.818 | ns |
| CCR7 + CD45RA + CD8+ | central memory CD4+ T cells | 78.27 15.01 | 41.47 35.87 | 0.0058 | 29.82 28.48 | <0.0001 | 40.00 29.99 | 0.0004 | 52.99 29.26 | 0.0255 |
| CCR7 + CD45RO + CD4+ | late-stage effector CD4+ T cells | 0.327 0.478 | 3.077 4.238 | 0.0122 | 3.732 4.866 | 0.0011 | 2.880 3.705 | 0.0127 | 0.946 1.400 | ns |
| CCR7 + CD45RO + CD4+ | Effector memory CD4+ T cells | 16.94 13.88 | 41.23 24.34 | 0.0256 | 51.36 23.66 | 0.0011 | 41.03 41.29 | 0.0015 | 32.64 22.00 | ns |
| CCR7 + CD45RA + CD8+ | naive CD8+ T cells | 4782 5.144 | 15.72 17.68 | ns | 12.01 9.707 | ns | 12.04 10.10 | ns | 9.618 9.818 | ns |
| CCR7 + CD45RO + CD8+ | central memory CD8+ T cells | 82.43 8.399 | 49.55 32.21 | 0.0078 | 37.00 25.43 | <0.0001 | 47.99 26.76 | <0.0001 | 59.71 23.89 | 0.0039 |
| CCR7 + CD45RA + CD8+ | late-stage effector CD8+ T cells | 0.246 0.568 | 3.077 4.238 | 0.0051 | 3.732 4.866 | <0.0001 | 2.880 3.705 | 0.0014 | 0.946 1.400 | 0.0326 |
| CCR7 + CD45RO + CD8+ | Effector memory CD8+ T cells | 2736 3220 | 34.71 25.88 | ns | 44.45 25.03 | <0.0001 | 41.76 24.72 | 0.0047 | 28.15 16.78 | ns |
Table 5
Correlation between cognitive parameter and indicated immune cell populations. Correlation analysis was performed between MMSE, ptau, htau, Q Albumin, Amyloid-β-1-40, Amyloid-β-1-42 and the Amyloid-β ratio and the frequency of CD14 + CD3+ monocytes, CD3+CD4+ T cells, CD56 + CD3+ NKT cells and CD56 + CD3- NK cells. Shown are the Spearman r value, the p value (two-tailed) and the p value summary. p values show the level of significance based on the reference provided.

| Parameter       | CD14 + CD3- | CD3+CD14+ | CD56 + CD3- | CD56+CD3+ |
|-----------------|-------------|------------|-------------|------------|
| MMSE | Spearman r | 0.3486 | 0.1616 | 0.0217 | 0.0734 |
| | P value (two-tailed) | 0.1998 | 0.0322 | ns | ns |
| | P value summary | ns | ns | ns | ns |
| Ptau | Spearman r | 0.6088 | 0.03382 | 0.1637 | 0.2071 |
| | P value (two-tailed) | 0.4221 | 0.6558 | 0.0300 | 0.0058 |
| | P value summary | ns | ns | ns | ns |
| Htau | Spearman r | 0.1014 | -0.02426 | 0.08755 | 0.1306 |
| | P value (two-tailed) | 0.1807 | 0.7492 | 0.2479 | 0.084 |
| | P value summary | ns | ns | ns | ns |
| Q Albumin | Spearman r | 0.02002 | -0.1514 | -0.0239 | -0.02668 |
| | P value (two-tailed) | 0.7974 | 0.0508 | 0.7592 | 0.7322 |
| | P value summary | ns | ns | ns | ns |
| Amyloid-β-1-40 | Spearman r | 0.3486 | -0.1456 | 0.1223 | 0.1087 |
| | P value (two-tailed) | <0.0001 | 0.0545 | 0.1068 | 0.0128 |
| | P value summary | **** | ns | ns | * |
| Amyloid-β-1-42 | Spearman r | -0.09623 | -0.04183 | -0.08646 | -0.09193 |
| | P value (two-tailed) | 0.2039 | 0.5815 | 0.2539 | 0.225 |
| | P value summary | ns | ns | ns | ns |
| Amyloid-β ratio | Spearman r | -0.4292 | 0.1073 | -0.2066 | -0.2625 |
| | P value (two-tailed) | <0.0001 | 0.1550 | 0.0074 | 0.0004 |
| | P value summary | **** | ns | ns | *** |

Table 6
Schematic presentation of alterations in CSF immune cells in dementia. Shown are changes in monocytes, NK(T) cells and subsets of CD4 and CD8 T cells in AD, FTD, and VD compared to non-demented elderly individuals. ↑ = increased, ↓ = decreased, ↔ = not changed.

| Cell subpopulation | AD | FTD | VD |
|--------------------|----|-----|----|
| CD14+ monocytes    | ↑  | ↔  | ↔  |
| CD56- NK cells     | ↑  | ↑  | ↑  |
| CD56 + CD3+ NKT cells | ↑  | ↔  | ↑  |
| CD4+ T cells       | ↑  | ↔  | ↔  |
| central memory     | ↓  | ↓  | ↓  |
| late-stage effector| ↑  | ↔  | ↔  |
| effector memory    | ↑  | ↑  | ↑  |
| CD8+ T cells       | Naive | ↔  | ↔  |
| central memory     | ↓  | ↓  | ↓  |
| late-stage effector| ↑  | ↑  | ↑  |
| effector memory    | ↑  | ↑  | ↑  |

unaltered between demented and non-demented controls, these observations raise the question about the relevance of Aj-specific B cells for brain pathology. Since anti-Aj antibodies were also detected in healthy individuals (Maetzler et al., 2011; Maifiet et al., 2012) their function remains to be further investigated in the same way as their level compared to healthy elderly people with other neurodegenerative disorders (Maifiet et al., 2013; Quet et al., 2014).

CD14+ monocytes were increased in CSF of AD patients, in particular in mild and moderate AD. These cells were positively correlated with Amyloid-β-1-40 and negatively correlated with the Amyloid-β ratio. Several authors provided data showing that activated inflammatory cells, in particular brain-resident microglia and infiltrated blood-borne monocyte-derived macrophages, are important for the physiological clearance of Ajβ (Koronyo-Hamaouiet al., 2009; El Khouryet al., 2007; Simard et al., 2006). CD14-positive microglia might act as a receptor for phagocytosing Amyloid-β in AD (Linet et al., 2005). Following phagocytosis, monocytes/macrophages might present Amyloid-β peptides to specific T cells. This results in the activation and differentiation of T cells. In addition, it was shown that ptau was correlated with microglial markers which indicated activation corresponding the number of T cells (Zotovaet al., 2013). Microglia were shown to accumulate in Amyloid-β plaques in brains of AD patients and release pro-inflammatory cytokines such as IL-1, IL-6, TNF-α and CRP (Akiyama et al., 2006; Svardageret al., 2010; Yasojima et al., 2000). These immune responses in the brain may have beneficial or detrimental roles (Rezaizadeh et al., 2009). The recruitment of peripheral CD14+ monocytes/macrophages could contrast the formation and extension of AJ plaques (Town et al., 2005a; Hawkes and McLaurin, 2009; Towneset al., 2005; Town et al., 2005b; Tanet al., 1999; Town et al., 2001). Investigations upon the integrity of the BBB/B-CSF-B in AD showed inconsistent results, with either an elevated CSF/serum albumin ratio in AD patients or no differences compared to controls. Nevertheless, it is known that cytokines such as IL-6, IL-1 or TNF-α influence the entry of immune cells in the brain (Elovaara et al., 1985; Wada, 1998; Mecocciet al., 1991). Moreover, increased CD3+ T cell numbers were detected in post mortem AD brain. These T cells accumulated in the hippocampus, the area with the most prominent neuronal damage (Togoet al., 2002). Nevertheless, it remains to be clarified to what extent antigen-loaded monocytes get into the periphery via CSF and activate T cells there.

In our study, NK and NKT cells were increased in CSF in AD (all stages including MCI), VD and FTD. NK cells express TLR2 and TLR4 which influence the entry of immune cells in the brain (Elovaara et al., 1985; Wada, 1998; Mecocco et al., 1991). Moreover, increased CD3+ T cell numbers were detected in post mortem AD brain. These T cells accumulated in the hippocampus, the area with the most prominent neuronal damage (Togoet al., 2002). Nevertheless, it remains to be clarified if what extent antigen-loaded monocytes enter the periphery via CSF and activate T cells there.
the MMSE score (Solteet al., 1998). In our study cohort, the level of ptau was increased in AD, but not in MCI, with decreasing values from mild to severe AD. This might be due to the fact that ptau is released after neuronal destruction in AD. The number of neurons that could release ptau is constantly decreasing. NKT cells might be involved in ptau-induced immunity.

Taken together, we found alterations in innate and adaptive immune cell populations, which were dependent on the type of dementia. Further analysis will gain further insight into the functional consequences of these changes.

5. Conclusions

Dementia is associated with specific changes in the immune system which could be detected in CSF. Our study determined alterations of innate and adaptive immune cells in CSF in AD, FTD and VD.

CD14+ monocytes in CSF were increased in mild and moderate AD. Moreover, NK and NKT cells were enhanced in AD, FTD and VD. Whereas the number of CD19+ B cells and total CD3+ T cells was unchanged in CSF, the T cell subpopulations were affected in demented patients. Central memory cells were reduced in all forms of dementia, while effector memory cells were enhanced in patients with AD and FTD compared to elderly controls.

Our finding might help to improve our understanding of the dementia-associated immune responses within the brain.

Declaration of competing interest

All authors declare that they have no conflict of interest.

References

Agrawal, S., Abud, E.M., Seigdha, S., Agrawal, A., 2018. IgM response against amyloid-beta in aging: a potential peripheral protective mechanism. Alzheimer’s Res. Ther. 10, 81.

Akiyama, H., et al., 2000. Inflammation and Alzheimer’s disease. Neurobiol. Aging 21, 383–421.

Araga, S., Kagimoto, H., Funamoto, K., Takahashi, K., 1991. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol. Scand. 84, 259–263.

Bang, J., Spina, S., Miller, B.L., 2015. Fronotemporal dementia. Lancet (Lond., Engl.) 386, 1672–1682.

Busse, M., et al., 2017. Alterations in the peripheral immune system in dementia. J. Alzheimers Dis. 58, 1303–1315.

Busse, M., et al., 2018. Dysfunction of the blood-cerebrospinal fluid-barrier and N-methyl-D-aspartate glutamate receptor antibodies in dementias. Eur. Arch. Psychiatr. Clin. Neurosci. 266, 483–492.

Castelo-Branco, C., Soveral, L., 2014. The immune system and aging: a review. Gynecol. Endocrinol. 30, 16–22.

Doyle, K.P., et al., 2015. B-lymphocyte-mediated delayed cognitive impairment following stroke. J. Neurosci. 35, 2133–2145.

El Khoury, J., et al., 2007. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13, 422–438.

Ferruci, L., Giallauria, F., Guralnik, J.M., 2008. Epidemiology of aging. Radiol. Clin. 46, 643–652.

Francisci, C., Gragnani, P., Parini, P., Giulinia, C., Santoro, A., 2018. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576–590.

Engelhardt, B., Ransohoff, R.M., 2005. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26, 485–495.

Farooq, M.U., Gorelick, P.B., 2013. Vascular cognitive impairment. Curr. Atherosclerosis Rep. 15, 230.

Garg, S.K., Banerjee, R., Kipnis, J., 2008. Neuroperotective immunity: T cell-derived glutamate endows astrocytes with a neuroprotective phenotype. J. Immunol. 180, 3866–3873.

Gordert, M., Eisenberg, D.S., Crowther, R.A., 2017. Propagation of tau aggregates and neurodegeneration. Annu. Rev. Neurosci. 40, 189–210.

Hawkes, C.A., McLaurin, J., 2009. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U. S. A 106, 1251–1256.

Henseka, M.T., et al., 2015. Neuroinflammation in Alzheimer’s disease. Lancet 14, 488–495.
Tan, J., et al., 1999. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286, 2352-2355.
Togo, T., et al., 2002. Occurrence of T cells in the brain of Alzheimer’s disease and other neurological diseases. J. Neuroimmunol. 124, 83-92.
Town, T., Tan, J., Mullan, M., 2001. CD40 signaling and Alzheimer’s disease pathogenesis. Neurochem. Int. 39, 371-380.
Town, T., Tan, J., Flavell, R.A., Mullan, M., 2005a. T-cells in Alzheimer’s disease. NeuroMolecular Med. 7, 255-264.
Town, T., Nikolic, V., Tan, J., 2005b. The microglial ‘activation’ continuum: from innate to adaptive responses. J. Neuroinflammation 2, 24.
Townsend, K.P., et al., 2005. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur. J. Immunol. 35, 901-910.
Udan, M.L., Ajit, D., Crouse, N.R., Nichols, M.R., 2008. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J. Neurochem. 104, 524-533.
Venegas, C., Heneka, M.T., 2019. Inflammasome-mediated innate immunity in Alzheimer’s disease. Faseb. J. 33, 13075-13084.
Wada, H., 1998. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Intern. Med. 37, 509-513.
Werring, D.J., Gregoire, S.M., Cipolotti, L., 2010. Cerebral microbleeds and vascular cognitive impairment. J. Neurol. Sci. 299, 131-135.
Wu, Y.T., et al., 2016. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet 15, 116-124.
Wu, H., et al., 2018. Pathogenic role of tissue-resident memory T cells in autoimmune diseases. Autoimmun. Rev. 17, 906-911.
Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L., 2000. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res. 887, 80-89.
Young, A.J., 1999. The physiology of lymphocyte migration through the single lymph node in vivo. Semin. Immunol. 11, 73-83.
Zotova, E., et al., 2013. Inflammatory components in human Alzheimer’s disease and after active amyloid-beta immunization. Brain 136, 2677-2696.
Zuroff, L., Daley, D., Blak, K.L., Koronyo-Hamaoui, M., 2017. Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes. Cell. Mol. Life Sci. 74, 2167-2201.